An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension
This study provides UT-15C (treprostinil diethanolamine) to eligible patients with pulmonary
arterial hypertension who have completed the TDE-PH-301, TDE-PH-302 or TDE-PH-308 studies.
The purpose of this study is to assess the long term safety of UT-15C and to assess the
effects of continued treatment with UT-15C on exercise capacity after one year of treatment.
Study Status: Active, not recruiting
Pulmonary Arterial Hypertension
Drug: Treprostinil diethanolamine
Information provided by:
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Florida
Weston, Florida 33331
The Cleveland Clinic Foundation
Cleveland, Ohio 44195
Kevin Laliberte, PharmD., Study Director